Dundee ends research coverage of biotech, tech

Dundee Capital Markets has ended research coverage of the biotechnology and technology sectors in the wake of Bank of Nova Scotia’s deal to acquire parent DundeeWealth, which also operates a major money management division. The move affects long-time biotech analysts David Martin and James Kao. As part of the transaction with Scotiabank, DundeeWealth is spinning [...]

Dundee calls Neptune new idea of interest

Dundee Capital Markets is highlighting Neptune Technologies and Bioressources (TSX-V:NTB; NASDAQ:NEPT) as a “new idea of interest,” with a “buy, speculative risk” rating, but no price target. Analyst David Martin writes that head-to-head data reported on Thursday by Neptune’s Acasti Pharma unit, comparing its CaPre fish oil against FDA-approved Lovaza, provides an “additional level of validation [...]

Prescription for growth

We, at biotuesdays.com, attended Dundee Capital Markets’ second emerging growth conference last week, where over 20 technology, life sciences and industrial growth companies presented. Dundee specializes in early-stage growth, and to say that the one-day showcase was jammed full of investment ideas is a bit of understatement. Here’s a sampling of what we took away [...]

Protox gets credibility boost from Warburg Pincus

An equity injection of up to $35 million from private equity giant Warburg Pincus represents a huge vote of confidence in Protox Therapeutics (TSX:PRX) and its lead PRX302 drug for enlarged prostate or benign prostatic hyperplasia (BPH), with the drug potentially able to target two other diseases: prostate cancer and prostatitis. “We went through an [...]

Labopharm’s new antidepressant to be ‘game-changer’

It’s game on for Labopharm (TSX:DDS; NASDAQ:DDSS). By February 11, the FDA is expected to approve the company’s antidepressant trazodone, a novel once-daily formulation that addresses many of the shortcomings of similar drugs on the market.  “I think it’s fair to say this drug could be a game-changer for us,” CEO James Howard-Tripp says in [...]

Waiting on Protox Phase 2b clinical results

Dundee Capital Markets says upcoming Phase 2b clinical results from Protox Therapeutics (TSX:PRX) may validate its prostate-targeted bacterial toxin PRX302 in men with benign prostate hyperplasia (BPH). In a New Idea of Interest, analyst David Martin writes that prior Phase 2a data supports the drug’s positive profile compared with leading minimally invasive therapies and BPH [...]